Dr. Aziz Ghahary is a professor and director of the Burn and Wound Healing Research Group at the University of British Columbia, Canada. He has published more than 190 peered reviewed articles and has received 13 million dollars as PI and Co-PI from major granting agencies such as CIHR, JDRF and MSFHR.
Ghahary has seven patents, one of which is related to identifying a high level of a biomarker for early detection of rheumatoid arthritis. This technology has so far generated three worldwide patents including one for its therapeutic use in treating rheumatoid arthritis patients. The test has clinically been approved in US under CLIA/FDA (IdentRA test), Health Canada (JOINTstat Test), CE marked (Europe) and TGA (Australia) and registration is underway in other countries. More than 100,000 Canadian have been tested and about 80% of them were positive for JOINTstat™ with a specificity of 96%. The test helps identify patients with joint pain with high risk of RA development and assists with RA diagnosis, joint damage prognosis and disease monitoring. Another patent is related to an anti-fibrotic agent for treatment of scarring and keloid. Upon a successful completing a phase I clinical trial, it has been licensed to a Canadian/US company, BirchBiomed in 2015. A phase 2 clinical trial has also been approved by Health Canada.
For an up-to-date list of publications by Dr. Ghahary, please see the ICORD website.